북미 로봇 보조 경피적 관상동맥 중재술(PCI) 시장 – 2030년까지의 산업 동향 및 예측

북미 로봇 보조 경피관상동맥중재술(PCI) 시장 분석 및 규모

미국 심장학회(ACC)와 미국 심장협회(AHA)의 데이터에 따르면 경피적 관상동맥 중재술(PCI)의 발생률은 수년에 걸쳐 꾸준히 증가해 왔습니다. 예를 들어, 미국에서는 거의 매년 약 120만 건의 PCI 시술이 수행되었습니다.

Data Bridge Market Research는 2022년에 8억 3,691만 달러였던 북미 로봇 지원 경피적 관상동맥 중재술(PCI) 시장이 2030년까지 1,344,010만 달러로 급증할 것이며 예측 기간 동안 6.1%의 CAGR을 보일 것으로 분석했습니다. "로봇 시스템"은 치료를 위한 더 나은 수술 방법에 대한 수요가 증가함에 따라 시장의 제품 유형 부문을 지배할 것으로 예상됩니다.

Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

북미 로봇 보조 경피적 관상동맥 중재술(PCI) 시장 범위 및 세분화

시장 정의

로봇 보조 경피적 관상동맥 중재술(PCI)은 정형외과적 부상과 시술자 피로의 위험을 줄이는 스텐트 이식을 위한 비수술적 접근 방식입니다. 로봇 보조 PCI는 폐쇄성 관상동맥 질환을 치료하고 막히거나 제한된 동맥을 여는 의료적 치료법입니다. 기존 PCI에 비해 로봇 보조 PCI는 성공률과 정확도가 더 높습니다.

북미 로봇 보조 경피관상동맥중재술(PCI) 시장 동향

운전자

• 심혈관 질환의 유병률 증가

North America has a high burden of cardiovascular diseases, including coronary artery disease. The increasing prevalence of these conditions drives the demand for advanced treatment options such as robot-assisted PCI.

• Increasing Demand for Minimally Invasive Procedures

Patients and healthcare providers are increasingly opting for minimally invasive procedures that offer shorter hospital stays, faster recovery, and reduced complications. Robot-assisted PCI provides a less invasive alternative to traditional open-heart surgery, leading to its growing demand in North America.

Opportunities

• Patient Demand for Advanced Treatment Options

Patients are increasingly seeking advanced treatment options that offer improved outcomes and faster recovery. The growing patient demand for minimally invasive procedures and the potential benefits of robot-assisted PCI present opportunities for healthcare providers to meet these demands and provide high-quality care.

• Increasing Healthcare Infrastructure and Investment

The robust healthcare infrastructure and investment in North America provide a supportive environment for the growth of robot-assisted PCI. Continued investment in healthcare facilities and access to advanced technologies can create opportunities for the adoption of robotic systems in PCI procedures.

Restraints/Challenges

• High Cost of Robot-Assisted Percutaneous Coronary Intervention (PCI) Instruments

The initial cost of acquiring robotic systems and the ongoing maintenance expenses can be significant. The high costs associated with robot-assisted PCI can limit its adoption, particularly in healthcare settings with budget constraints or reimbursement limitations.

• Limited Clinical Evidence

While robot-assisted PCI has shown promising results, there may be a need for more robust clinical evidence to support its widespread adoption. Long-term data on patient outcomes, cost-effectiveness, and comparative studies with traditional PCI procedures can help address any skepticism and encourage greater acceptance of robot-assisted intervention (PCI).

The North America robot assisted Percutaneous Coronary Intervention (PCI) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on this market, contact Data Bridge Market Research for an analyst brief. Our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In January 2021, MicroPort announced the successful completion of the 10,000th implantation of its Firehawk Rapamycin Target Eluting Coronary Stent System. The achievement highlighted the continued adoption and clinical use of the company's stent system in robotic-assisted PCI procedures
• In June 2020, Auris Health announced the FDA clearance of its Monarch Platform for robotic-assisted bronchoscopic procedures. While not specifically focused on PCI, this development showcased the potential of Auris Health's robotic-assisted technology in minimally invasive interventions.

North America Robot Assisted Percutaneous Coronary Intervention (PCI) Market Scope

The North America robot assisted Percutaneous Coronary Intervention (PCI) market is segmented into two notable segments based on product type and end-user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Robotic Systems
• Instruments
• Accessories

 End-User

• Hospitals
• Path Labs
• Others

North America Robot Assisted Percutaneous Coronary Intervention (PCI) Market Regional Analysis/Insights

The North America robot assisted Percutaneous Coronary Intervention (PCI) market is analyzed and market size insights and trends are provided by product type and end-users as referenced above.

The countries covered in this market report are U.S., Canada, and Mexico.

The U.S. is expected to dominate the North America robot assisted Percutaneous Coronary Intervention (PCI) market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having cardiac disorders.   

The U.S. is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people, and the growing demand for advanced medical technology for coronary diseases, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

북미 로봇 보조 경피적 관상동맥 중재술(PCI) 시장은 자본 장비에 대한 모든 국가의 의료 지출 증가, 북미 로봇 보조 경피적 관상동맥 중재술(PCI) 시장의 다양한 제품 설치 기반, 수명선 곡선을 사용하는 기술의 영향, 의료 규제 시나리오의 변화 및 시장에 미치는 영향에 대한 자세한 시장 분석을 제공합니다.

경쟁 환경 및 북미 로봇 보조 경피적 관상동맥 중재술(PCI) 시장 점유율 분석

북미 로봇 보조 경피적 관상동맥 중재술(PCI) 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

북미 로봇 보조 경피적 관상동맥 중재술(PCI) 시장에서 활동하는 주요 업체는 다음과 같습니다.

• 코린더스 주식회사(미국)
• Robocath, Inc. (프랑스)
• 스미스+네퓨(영국)
• 메드트로닉(아일랜드)
• CMR Surgical Ltd. (영국)
• Renishaw plc. (영국)
• KUKA AG(독일)
• Auris Health, Inc. (미국)
• Intuitive Surgical, Inc(미국)
• 메드로보틱스 코퍼레이션(미국)
• CorPath Robotics(Siemens Healthineer의 자회사)(미국)
• ROBODOC(큐렉소테크놀로지코퍼레이션) (미국)

SKU-44773